Your browser version may not work well with NCBI's Web applications. More information here...
1: Respir Res. 2001;2(3):164-8. Epub 2001 Apr 5.Click here to read Click here to read Links

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important antituberculosis drugs: isoniazid, rifampin, and pyrazinamide. On the basis of this information, more exacting laboratory testing, and ultimately more appropriate and timely treatment regimens, can be developed.

PMID: 11686881 [PubMed - indexed for MEDLINE]

PMCID: PMC2002067

Patient Drug Information